Figshare
open access
CC BY-NC-ND 4.0
Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer#442090
- Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial#140997
- Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma#889420
- Neoadjuvant Pazopanib in Renal Cell Carcinoma#847894
- Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments#979292
Record · ID 475599
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive